FDA approves Viekira Pak to treat hepatitis C
The FDA approved Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) to treat patients with chronic hepatitis C virus genotype 1 infection, including those with a type of advanced liver disease called cirrhosis. Viekira Pak is marketed by AbbVie.
December 19, 2014